Brief: Puma Biotechnology Announces FDA Clearance Of IND For Alisertib In Small Cell Lung Cancer

Puma Biotechnology

08/08/2023 14:26

Aug 8 (Reuters) - Puma Biotechnology Inc  PBYI.O :
    * PUMA BIOTECHNOLOGY ANNOUNCES FDA CLEARANCE OF IND FOR
ALISERTIB
IN SMALL CELL LUNG CANCER
    * PUMA BIOTECHNOLOGY INC - ANTICIPATES INITIATING PHASE II
TRIAL
IN SECOND HALF OF 2023
    * PUMA BIOTECHNOLOGY INC: PRIMARY ENDPOINT OF TRIAL WILL BE
OBJECTIVE RESPONSE RATE
    * PUMA BIOTECHNOLOGY: SECONDARY ENDPOINTS OF OF TRIAL WILL
BE
DURATION OF RESPONSE, DISEASE CONTROL RATE, PROGRESSION FREE
SURVIVAL AND OVERALL SURVIVAL
    * PUMA BIOTECHNOLOGY INC: ANTICIPATES MEETING WITH FDA TO
EXPLORE
POTENTIAL FOR AN ACCELERATED APPROVAL PATHWAY FOR ALISERTIB IN
SMALL CELL LUNG CANCER

Source text for Eikon:  ID:nBw6x0KM4a 
Further company coverage:  PBYI.O